Novartis says MS drug reduces relapse in patients

Related Content

No related items were found.

BASEL, Switzerland An investigational drug made by Novartis for multiple sclerosis reduced annual relapse rates in new patients by 62% compared with placebo, according to data from a two-year, late-stage clinical trial the Swiss drug maker showed Tuesday at a scientific meeting.

Presenting results from the phase 3 FREEDOMS trial at the annual meeting of the American Academy of Neurology, Novartis said the once-daily pill Gilenia (fingolimod) administered in 0.5 mg doses also reduced relapses by 44% in patients who had previously taken other treatments while delaying the progression of disability by 30%.

“These findings reinforce the potential for Gilenia to be a breakthrough therapy option for physicians and people with relapsing forms of MS,” Novartis Pharma global head of development Trevor Mundel said.

© 2014 Drug Store News. All Rights Reserved.